Mazyar Shadman, M.D., M.P.H.
Mazyar Shadman, M.D., M.P.H.
Associate Professor
Clinical Research Division, Fred Hutch
Dr. Mazyar Shadman is a blood cancer specialist who focuses on lymphoid malignancies. He is involved in clinical research using novel therapeutic agents for lymphoma and chronic lymphocytic leukemia, or CLL, as well as immunotherapy (specifically CAR T cell therapy) for lymphoid neoplasms and blood stem cell transplant for hematologic malignancies. His goal is to identify the best treatment sequence or combination for patients with high-risk lymphoma and CLL.
Other Appointments & Affiliations
Attending Physician, Hematologic Malignancies
Seattle Cancer Care Alliance
Assistant Professor, Medical Oncology Division
University of Washington School of Medicine
Education
M.D., Tehran University of Medical Sciences, 2004
Internal Medicine Residency, Cleveland Clinic, 2008-2011
Hematology and Medical Oncology fellowship, University of Washington/Fred Hutchinson Cancer Research Center, 2011-2014
M.P.H., Cancer Epidemiology, University of Washington, 2008
Research Interests
Therapeutic clinical trials in lymphoid malignancies with a focus on chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Clinical outcome research in hematopoietic cell transplantation
Epidemiology of hematologic malignancies
Active Clinical Trials
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Study Number: 9738
Phase: I/II
Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Study Number: S1608
Phase: II
An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Study Number: 9703
Phase: III
Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
Study Number: 9727
Phase: I/II
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Study Number: 9837
Phase: I
A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Study Number: 9905
Phase: III
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Study Number: RG1003500
Phase: III
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210.